| Literature DB >> 28533536 |
Zhanwei Zhao1, Zifang Yin2, Zhenning Hang1, Gang Ji1, Quanxin Feng1, Qingchuan Zhao3.
Abstract
The feasible of minimally invasive pancreaticoduodenectomy (MIPD) remains controversial when compared with open pancreaticoduodenectomy (OPD). We conducted a systemic review and meta-analysis to summarise the available evidence to compare MIPD vs OPD. We systemically searched PubMed, EMBASE and Web of Science for studies published through February 2016. The primary endpoint was postoperative pancreatic fistula (POPF, grade B/C). A total of 27 studies involving 14,231 patients (2,377 MIPD and 11,854 OPD) were included. MIPD was associated with longer operative times (P < 0.01) and increased mortality (P < 0.01), but decreased estimated blood loss (P < 0.01), decreased delayed gastric emptying (P < 0.01), increased R0 resection rate (P < 0.01), decreased wound infection (P = 0.03) and shorter hospital stays (P < 0.01). There were no significant differences in BMI (P = 0.43), tumor size (P = 0.17), lymph nodes harvest (P = 0.57), POPF (P = 0.84), reoperation (P = 0.25) and 5-year survival rates (P = 0.82) for MIPD compared with OPD. Although there was an increased operative cost (P < 0.01) for MIPD compared with OPD, the postoperative cost was less (P < 0.01) with the similar total costs (P = 0.28). MIPD can be a reasonable alternative to OPD with the potential advantage of being minimally invasive. However, MIPD should be performed in high-volume centers and more randomized-controlled trials are needed to evaluate the appropriate indications of MIPD.Entities:
Mesh:
Year: 2017 PMID: 28533536 PMCID: PMC5440387 DOI: 10.1038/s41598-017-02488-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of included studies.
| First author | Year | Country | Study type | Study period | Center performing | Study populationMIPD/OPD | Cancers MIPD/OPD | Type of MIPD | Mortality (n) MIPD/OPD | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| Cho[ | 2009 | Japan | Retrospective | 2007–2008 | 1 | 15/15 | 8/15 | LPD (LPPPD) | 0/0 | 7 |
| Buchs[ | 2011 | USA | Retrospective | 2002–2010 | 1 | 44/39 | 33/27 | RLPD | 2/1 | 7 |
| Zhou[ | 2011 | China | Retrospective | 2009 Jan–Dec | 1 | 8/8 | 8/8 | RLPD | 0/1 | 6 |
| Zureikat[ | 2011 | USA | Retrospective | 2008–2010 | 1 | 14/14 | 13/12 | LPD | 7/0 | 7 |
| Asbun[ | 2012 | USA | Retrospective | 2005–2011 | 1 | 53/215 | 51/195 | LPD/TLPD/LPPPD | 3/19 | 9 |
| Chalikonda[ | 2012 | USA | Retrospective | 2009–2010 | 1 | 30/30 | 18/18 | RLPD | 1/0 | 8 |
| Kuroki[ | 2012 | Japan | Retrospective | 2008–2010 | 1 | 20/31 | 20/30 | LPD/LPPPD/LSSPPD | NR | 5 |
| Lai[ | 2012 | China | Retrospective | 2000–2012 | 1 | 20/67 | 15/53 | RLPD | 0/3 | 6 |
| Mesleh[ | 2013 | USA | Retrospective | 2009–2012 | 1 | 75/48 | 73/42 | LPD | NR | 6 |
| Bao[ | 2014 | USA | Retrospective | 2009–2011 | 1 | 28/28 | 19/26 | LPD | 2/2 | 7 |
| Croome[ | 2014 | USA | Retrospective | 2008–2013 | 1 | 108/214 | NR | TLPD | 1/4 | 9 |
| Hakeem[ | 2014 | UK | Retrospective | 2005–2009 | 1 | 12/12 | 12/12 | LPD | 3/6 | 6 |
| Langan[ | 2014 | USA | Retrospective | 2010–2013 | 1 | 28/25 | 16/16 | LPD | NR | 6 |
| Speicher[ | 2014 | USA | Retrospective | 2010–2013 | 1 | 56/84 | 45/62 | LPD/TLPD | 3/6 | 8 |
| Wang[ | 2014 | Canada | Retrospective | 2009–2013 | 1 | 13/20 | 10/15 | LPD | 1/4 | 7 |
| Wellner[ | 2014 | Germany | Retrospective | 1996–2013 | 2 | 40/40 | 28/28 | LPD (LPPPD) | 0/1 | 7 |
| Adam[ | 2015 | USA | Retrospective | 2010–2011 | NR | 983/6078 | 831/5234 | LPD | 50/188 | 7 |
| Baker[ | 2015 | USA | Retrospective | 2012–2013 | 1 | 22/49 | 18/40 | RLPD | 0/2 | 7 |
| Chen[ | 2015 | China | Prospective | 2010–2013 | 1 | 60/120 | 38/76 | RLPD | 1/3 | 8 |
| Dokmak[ | 2015 | France | Retrospective | 2011–2014 | 1 | 46/46 | 40/38 | LPD | 1/0 | 8 |
| Liang[ | 2015 | Canada | Retrospective | 2011–2013 | 1 | 15/29 | 9/23 | LPD/TLPD | 1/1 | 6 |
| Mendoza[ | 2015 | Korea | Retrospective | 2014 Jun–Dec | 1 | 18/34 | 14/31 | LPD | NR | 5 |
| Senthilnathan[ | 2015 | India | Retrospective | 2006–2011 | 1 | 45/118 | NR | LPD/LPPPD | NR | 6 |
| Sharpe[ | 2015 | USA | Retrospective | 2010–2011 | 9 | 384/4037 | NR | LPD | 20/150 | 7 |
| Song[ | 2015 | Korea | Retrospective | 2007–2012 | 1 | 97/198 | 93/167 | LPD (LPPPD) | 0/0 | 8 |
| Tan[ | 2015 | China | Retrospective | 2009–2014 | 1 | 30/30 | 27/26 | TLPD | 0/1 | 6 |
| Tee[ | 2015 | USA | Retrospective | 2007–2014 | 1 | 113/225 | 75/192 | LPD/TLPD/LPPPD | 5/3 | 7 |
MIPD: minimally invasive pancreaticoduodenectomy; OPD: open pancreaticoduodenectomy; LPD: laparoscopic pancreaticoduodenectomy; TLPD: total laparoscopic pancreaticoduodenectomy; LPPPD: laparoscopic pylorus-preserving pancreaticoduodenectomy; LSSPPD: laparoscopic subtotal stomach-preserving pancreaticoduodenectomy; RLPD: robotic-assisted laparoscopic pancreaticoduodenectomy; NOS: Newcastle-Ottawa Scale; NR: no record.
Meta-analysis of different outcomes variables.
| Variable | Included studies | Patients (n) MIPD/OPD | OR/WMD | 95% CI |
|
|
|
|---|---|---|---|---|---|---|---|
| Age (year) | 18 | 2052/11483 | 1.44 | −0.60, 3.48 | 0.17 | <0.01 | 90 |
| Sex (male) | 26 | 1993/10817 | 0.99 | 0.76, 1.30 | 0.94 | <0.01 | 71 |
| ASA score | 2 | 59/54 | 0.03 | −0.60, 0.67 | 0.92 | <0.01 | 89 |
| Cancers | 22 | 1840/7485 | 0.95 | 0.70, 1.30 | 0.76 | <0.01 | 51 |
| Tumor size (cm) | 14 | 1854/11068 | −0.06 | −0.15, 0.03 | 0.17 | 0.02 | 49 |
| Mortality | 21 | 2068/11600 | 1.42 | 1.13, 1.80 |
| 0.53 | 0 |
| BMI (Kg/m2) | 16 | 703/1195 | −0.31 | −1.09, 0.46 | 0.43 | <0.01 | 77 |
| Operative time (min) | 17 | 687/1174 | 67.37 | 25.11, 109.63 |
| <0.01 | 95 |
| Estimated blood loss (mL) | 14 | 597/1061 | −324.47 | −492.37, −156.57 |
| <0.01 | 93 |
| R0 | 19 | 749/4195 | 1.40 | 1.15, 1.70 | < | 0.94 | 0 |
| Lymph node harvest | 17 | 896/5204 | 0.36 | −0.88, 1.61 | 0.57 | <0.01 | 73 |
| POPF | 23 | 933/1491 | 0.98 | 0.77, 1.24 | 0.84 | 0.96 | 0 |
| Delayed gastric emptying | 18 | 814/1330 | 0.64 | 0.48, 0.84 |
| 0.84 | 0 |
| Wound infection | 14 | 520/958 | 0.71 | 0.53, 0.96 |
| 0.07 | 38 |
| Length of hospital stay (days) | 15 | 948/5005 | −3.14 | −4.42, −1.87 | < | <0.01 | 69 |
| Re-operation | 13 | 518/873 | 0.78 | 0.51, 1.19 | 0.25 | 0.45 | 0 |
| Operative cost ($) | 3 | 147/295 | 6663.75 | 2079.60, 11247.91 |
| <0.01 | 99 |
| Postoperative cost ($) | 4 | 124/220 | −550.76 | −652.24 −449.29 | < | 0.32 | 14 |
| Total cost ($) | 4 | 213/428 | 3018.56 | −3359.60, 9396.72 | 0.35 | <0.01 | 88 |
| 5-year survival | 3 | 142/709 | 1.14 | 0.37, 3.46 | 0.82 | 0.66 | 0 |
P value: P value for the overall effect; P h: P value for heterogeneity; ASA: American Society of Anesthesiologists; BMI: body mass index (Kg/m2); POPF: clinically relevant postoperative pancreatic fistula; OR: odds ratio; WMD: weight mean difference. Bold text indicates statistical significance.
Subgroup analyses of MIPD vs OPD.
| n | OR (95% CI) |
|
|
| |
|---|---|---|---|---|---|
|
| 23 | 0.98 (0.77–1.24) | 0.96 | 0 | 0.84 |
|
| |||||
| LPD | 17 | 1.01 (0.77–1.32) | 0.98 | 0 | 0.95 |
| RLPD | 6 | 0.85 (0.50–1.46) | 0.38 | 5 | 0.55 |
|
| |||||
| Europe | 3 | 1.11 (0.59–2.08) | 0.28 | 21 | 0.75 |
| America | 12 | 0.97 (0.72–1.31) | 0.97 | 0 | 0.85 |
| Asia | 8 | 0.91 (0.55–1.51) | 0.61 | 0 | 0.72 |
|
| |||||
| <100 | 16 | 1.01 (0.70–1.45) | 0.89 | 0 | 0.98 |
| ≥100 | 7 | 0.95 (0.70–1.30) | 0.79 | 0 | 0.77 |
|
| |||||
| Before 2014 | 9 | 1.20 (0.74–1.94) | 0.87 | 0 | 0.47 |
| 2014 or later | 14 | 0.91 (0.70–1.20) | 0.89 | 0 | 0.52 |
|
| |||||
| <7 stars | 8 | 1.40 (0.80–2.47) | 0.77 | 0 | 0.24 |
| ≥7 stars | 15 | 0.90 (0.69–1.17) | 0.97 | 0 | 0.45 |
P s: P value for heterogeneity within each subgroup; Pt: test for overall effect; I : I value for heterogeneity within each subgroup.